Bio-Rad enhances multiplex flow cytometry with three new StarBright ultraviolet dyes
The StarBright UltraViolet 510, StarBright UltraViolet 665, and StarBright UltraViolet 795 Dyes Offer Exceptional Brightness with Narrow Excitation and Emission Profiles to Support Multiplex Panels
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today introduced three StarBright™ Dyes designed for use with a 355 nanometer UV laser in flow cytometry applications. StarBright UltraViolet 510, 665, and 795 Dyes offer exceptional brightness with narrow excitation and emission profiles for precise resolution, expanding Bio-Rad’s range to provide greater flexibility in multicolor flow cytometry panels.
Bio-Rad’s line of StarBright Dyes offers researchers unique fluorescent nanoparticles conjugated to highly validated flow antibodies, which are compatible with most experimental protocols and flow cytometers, including Bio-Rad’s ZE5 Cell Analyzer and S3e Cell Sorter. The dyes are resistant to photobleaching and are highly stable with no loss of signal in fixation, and minimal lot-to-lot variation helps to ensure consistent staining and deliver reliable results.
“We are proud to add three new dyes to Bio-Rad’s StarBright UltraViolet portfolio, following its launch last year, and are now better positioned to support researchers with their flow cytometry workflows by providing a range of high-performance dyes excitable by the 355 nanometer UV laser to existing alternatives,” said Mike Blundell, PhD, Bio-Rad Product Manager, Flow Cytometry, Life Science Group. “The unrivaled brightness of the dyes enables enhanced resolution of low-density antigens and rare populations while maintaining consistent and reproducible staining without the need for special buffers.”
Visit bio-rad-antibodies.com/flow-cytometry-starbright-ultraviolet-dyes.html for more information about the StarBright UltraViolet 510, StarBright UltraViolet 665, and StarBright UltraViolet 795 Dyes.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,900 employees worldwide. Bio-Rad had revenues of $2.9 billion in 2021. For more information, visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, supply chain risks, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Kate Smith, Director, Global Customer Engagement Marketing
510-741-5307
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885